The findings of Nielsen et al. regarding improvements in HbA1c with ETI therapy, albeit without corresponding changes in insulin requirements or glucose profiles in patients with established CFRD, highlight the complex relationship between CFTR function and glucose metabolism [24]. The gene discussed is CFTR; the disease is cystic fibrosis-related diabetes.